02 julio 2009
Zeltia 5,55 euros a 8 sesiones del bis a bis J&J con la FDA Yondelis Ovario ... en cuanto a la EMEA pues tiempo hace que predican tiempos paralelos .
Wednesday 15 July 2009 at 08:00 AM Ends: Wednesday 15 July 2009 at 02:00 PM
Location: Gaithersburg, Md. USA
ONCOLOGIC DRUGS ADVISORY COMMITTEE
DATE: July 15, 0800/1200
LOCATION: Hilton, 620 Perry Parkway, Gaithersburg, Md.
CONTACT: Nicole Vesely, 301-827-6793
The committee will discuss a new drug application from Johnson&Johnson for trabectedin intravenous infusion in combination with Doxil for the treatment of patients with relapsed ovarian cancer. The proposed trade name for trabectedin is Yondelis.
The committee also will discuss a supplemental new drug application from Johnson&Johnson for intravenous infusion of Doxil in combination with docetaxel for the treatment of patients with locally advanced or metastatic breast cancer who have received prior anthracycline treatment.